Batavia Biosciences focuses on accelerating the transition of biopharmaceutical product candidates from discovery to the clinic with improved success and lower cost. We are your flexible partner to rely on at all stages of biopharmaceutical process development.
To accelerate the journey to the clinic, the company offer a full range of development and manufacturing services for all major classes of biopharmaceutical, and has developed a portfolio of technologies aimed to improve product yield, reduce process development time and increase product stability. These technologies have amply demonstrated to reduce risks, improve speed and reduce costs in biopharmaceutical development to make sure to product receives the patient without any unnecessary delay.
The company employs a highly educated staff with many years of experience in DNA cloning, mammalian cell line generation, upstream process development (mammalian, microbial & insect cell platforms), purification development, product characterization, and clinical manufacturing. As such the company, with laboratories in USA and the Netherlands, is well positioned to take on any challenge associated with the development of complex biological medicines be it proteins, antibodies, vaccines or viral vectors.
Batavia Biosciences was founded in 2010 by Chris Yallop and Menzo Havenga. Chris build his career first on recombinant proteins and antibodies, while Menzo did the same on vaccines and viral vectors. During their career, they experienced both the benefits and hurdles associated with outsourcing. Using that experience they decided to build their own contract development and manufacturing organization, positioned to help clients from an early idea through process development into clinical GMP manufacturing.
Batavia Biosciences actively develops know-how and technologies to support global health initiatives and the biopharmaceutical industry to bring new and improved medicines to the market.